Monopar stock falls 20% amid preliminary phase 1 data for cancer drug camsirubicin

Nov. 16, 2022 7:41 AM ETMonopar Therapeutics Inc. (MNPR)By: Ravikash, SA News Editor

Two scientists in conversation, standing in laboratory

Solskin

  • Monopar Therapeutics (NASDAQ:MNPR) reported data from an ongoing phase 1b trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS).
  • Camsirubicin is a novel proprietary analog of cancer drug doxorubicin.
  • The phase 1b trial enrolled 11 patients. Five out

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.